Inhibitors of HIV-1 protease: 10 years after

Bibliography

• DE CLERCQ E: New approaches toward anti-HIV chemotherapy. J. Med. Chem. (2005) 48:1297-1313.
   PubMed Web of Science ®Google Scholar
• DE CLERCQ E: Antivirals and antiviral strategies. Nature Drug Discov. (2002) 1:13-25.
   PubMed Web of Science ®Google Scholar
• RICHMAN DD: HIV chemotherapy. Nature (2001) 410:995-1001.
   PubMed Web of Science ®Google Scholar
• BARBARO G, SCOZZAFAVA A, MASTROLORENZO A, SUPURAN CT: Highly active antiretroviral therapy: current state of the art, new agents and their pharmacological interactions useful for improving therapeutic outcome. Curr. Pharm. Des. (2005) 11:1805-1843.
   PubMed Web of Science ®Google Scholar
• DE CLERCQ E: New developments in anti-HIV chemotherapy. Curr. Med. Chem. (2001) 8:1543-1572.
   PubMed Web of Science ®Google Scholar
• SCOZZAFAVA A, OWA T, MASTROLORENZO A, SUPURAN CT: Anticancer and antiviral sulfonamides. Curr. Med. Chem. (2003) 10:925-953.
   PubMed Web of Science ®Google Scholar
• GREENE WC, PETERLIN M: Charting HIV's remarkable voyage through the cell: basic science as a passport to future therapy. Nature Med. (2002) 8:673-680.
   PubMed Web of Science ®Google Scholar
• SHEEHY AM, GADDIS NC, MALIM MH: The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif. Nature Med. (2003) 9:1404-1407.
   PubMed Web of Science ®Google Scholar
• MARIN M, ROSE KM, KOZAK SL, KABAT D: HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation. Nature Med. (2003) 9:1398-1403.
   PubMed Web of Science ®Google Scholar
• ZHANG H, YANG B, POMERANTZ RJ, ZHANG C, ARUNACHALAM SC, GAO L: The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA. Nature (2003) 424:94-98.
   PubMed Web of Science ®Google Scholar
• OGDEN RC, FLEXNER CW: Protease Inhibitors in AIDS Therapy. (Eds) Marcel Dekker, New York, Basel, USA (2001).
   Google Scholar
• ERICKSON JW: HIV-1 protease as a target for AIDS therapy. In: Protease inhibitors in AIDS therapy. Ogden RC, Flexner CW (Eds) Marcel Dekker, New York, USA (2001):1-25.
   Google Scholar
• SCOZZAFAVA A, MASTROLORENZO A, SUPURAN CT: Non-peptidic chemokine receptors antagonists as emerging anti-HIV agents. J. Enzyme Inhib. Med. Chem. (2002) 17:69-76.
   PubMed Web of Science ®Google Scholar
• SCHECHTER I, BERGER A: On the size of the active site in proteases. Biochem. Biophys. Res. Commun. (1967) 27:157-162.
   PubMed Web of Science ®Google Scholar
• CASINI A, SCOZZAFAVA A, SUPURAN CT: Sulfonamide derivatives with protease inhibitory action as anticancer, antiinflammatory and antiviral agents. Expert Opin. Ther. Pat. (2002) 12:1307-1327.
   Web of Science ®Google Scholar
• SUPURAN CT, CASINI A, SCOZZAFAVA A: Protease inhibitors of the sulfonamide type: anticancer, anti-inflammatory and antiviral agents. Med. Res. Rev. (2003) 23:535-558.
   PubMed Web of Science ®Google Scholar
• WLODAWER A, GUSTCHINA A: Structural and biochemical studies of retroviral proteases. Biochim. Biophys. Acta. (2000) 1477:16-34.
   PubMed Web of Science ®Google Scholar
• TOMASSELLI AG, HEINRIKSON RL: Targeting the HIV-protease in AIDS therapy: a current clinical perspective. Biochim. Biophys. Acta (2000) 1477:189-214.
   PubMed Web of Science ®Google Scholar
• DUNCAN IB, REDSHAW S: Discovery and early development of saquinavir. In: Protease inhibitors in AIDS therapy. Ogden RC, Flexner CW (Eds) Marcel Dekker, New York, USA (2001):27-47.
   Google Scholar
• KEMPF DJ: Discovery and early development of ritonavir and ABT-378. In: Protease inhibitors in AIDS therapy. Ogden RC, Flexner CW (Eds) Marcel Dekker, New York, USA (2001):49-64.
   Google Scholar
• DORSEY BD, VACCA JP: Discovery and early development of indinavir. In: Protease inhibitors in AIDS therapy. Ogden RC, Flexner CW (Eds) Marcel Dekker, New York, USA (2001):65-83.
   Google Scholar
• REICH SH: Discovery and early development of nelfinavir (Viracept). In: Protease inhibitors in AIDS therapy. Ogden RC, Flexner CW (Eds) Marcel Dekker, New York, USA (2001):85-99.
   Google Scholar
• TUNG RD, LIVINGSTON DJ, RAO BG et al.: Design and synthesis of amprenavir, a novel HIV protease inhibitor. In: Protease inhibitors in AIDS therapy. Ogden RC, Flexner CW (Eds) Marcel Dekker, New York, USA (2001):101-118.
   Google Scholar
• CHRUSCIEL RA, THAISRIVONGS S, NICHOLAS JA: HIV protease inhibitors in early development. In: Protease inhibitors in AIDS therapy. Ogden RC, Flexner CW (Eds), Marcel Dekker, New York, USA (2001):119-137.
   Google Scholar
• QAZI NA, MORLESE JF, POZNIAK AL: Lopinavir/ritonavir (ABT-378/r). Exp. Opin. Pharmacother. (2002) 3:315-327.
   PubMedGoogle Scholar
• RUSCONI S, LA SETA CATAMANCIO S: HIV-1 protease inhibitors in development. Expert Opin. Investig. Drugs (2002) 11:387-395.
   PubMedGoogle Scholar
• WITHERELL G: BMS-232632 (Novartis/Bristol-Myers Squibb). Curr. Opin. Invest. Drugs (2001) 2:340-347.
   PubMedGoogle Scholar
• PILIERO PJ: Atazanavir: a novel HIV-1 protease inhibitor. Expert Opin. Investig. Drugs (2002) 11:1295-1301.
   PubMed Web of Science ®Google Scholar
• GATELL JM: From amprenavir to GW433908. J. HIV Ther. (2001) 6:95-99.
   PubMedGoogle Scholar
• QUERCIA R, GARNIER E, FERRE V et al.: Salvage therapy with ritonavir- boosted amprenavir/fosamprenavir: virological and immunological response in 2 years follow-up. HIV Clin. Trials (2005) 6:73-80.
   PubMed Web of Science ®Google Scholar
• ARVIEUX C, TRIBUT O: Amprenavir or fosamprenavir plus ritonavir in HIV infection: pharmacology, efficacy and tolerability profile. Drugs (2005) 65:633-659.
   PubMedGoogle Scholar
• BECKER S, THORNTON L: Fosamprenavir: advancing HIV protease inhibitor treatment options. Expert Opin. Pharmacother. (2004) 5:1995-2005.
   PubMed Web of Science ®Google Scholar
• FLEXNER CW: Pharmacology and drug interactions of HIV protease inhibitors. In: Protease inhibitors in AIDS therapy. Ogden RC, Flexner CW (Eds) Marcel Dekker, New York, USA (2001):139-159.
   Google Scholar
• FLEXNER CW: Beneficial pharmacokinetic interactions: are two protease inhibitors better than one ? In: Protease inhibitors in AIDS therapy. Ogden RC, Flexner CW (Eds) Marcel Dekker, New York, USA (2001):161-177.
   Google Scholar
• KAPLAN SS, HICKS CB: Safety and antiviral activity of lopinavir/ritonavir-based therapy in human immunodeficiency virus type 1 (HIV-1) infection. J. Antimicrob. Chemother. (2005) 56:273-276.
   PubMed Web of Science ®Google Scholar
• BONFANTI P, MARTINELLI C, RICCI E et al.; CISAI GROUP (ITALIAN COORDINATORS FOR THE STUDY OF ALLERGIES HIV INFECTION): An Italian approach to postmarketing monitoring: preliminary results from the SCOLTA (Surveillance Cohort Long-Term Toxicity Antiretrovirals) project on the safety of lopinavir/ritonavir. J. Acquir. Immune Defic. Syndr. (2005) 39:317-20.
   PubMed Web of Science ®Google Scholar
• ARRIBAS JR, PULIDO F, DELGADO R et al.: Lopinavir/ritonavir as single-drug therapy for maintenance of HIV-1 viral suppression: 48-week results of a randomized, controlled, open-label, proof-of-concept pilot clinical trial (OK Study). J. Acquir. Immune Defic. Syndr. (2005) 40:280-287
   PubMed Web of Science ®Google Scholar
• ANANWORANICH J, KOSALARAKSA P, HILL A et al.; HIV-NAT 017 STUDY TEAM: Pharmacokinetics and 24-week efficacy/safety of dual boosted saquinavir/lopinavir/ritonavir in nucleoside-pretreated children. Pediatr. Infect. Dis. J. (2005) 24:874-879.
   PubMed Web of Science ®Google Scholar
• FUSTER D, CLOTET B: Review of atazanavir: a novel HIV protease inhibitor. Expert Opin. Pharmacother. (2005) 6:1565-1572
   PubMed Web of Science ®Google Scholar
• FELDT T, OETTE M, KROIDL A et al.: Atazanavir for treatment of HIV infection in clinical routine: efficacy, pharmacokinetics and safety. Eur. J. Med. Res. (2005) 10:7-10.
   PubMedGoogle Scholar
• PILIERO PJ: Atazanavir: a novel once-daily protease inhibitor. Drugs Today. (2004) 40:901-912.
   PubMedGoogle Scholar
• LE TIEC C, BARRAIL A, GOUJARD C, TABURET AM: Clinical pharmacokinetics and summary of efficacy and tolerability of atazanavir. Clin. Pharmacokinet. (2005) 44:1035-1050.
   PubMed Web of Science ®Google Scholar
• TURNER SR, STROHBACH JW, TOMMASI RA et al.: Tipranavir (PNU-140690): a potent, orally bioavailable nonpeptidic HIV protease inhibitor of the 5,6-dihydro-4- hydroxy-2-pyrone sulfonamide class. J. Med. Chem. (1998) 41:3467-3476.
   PubMed Web of Science ®Google Scholar
• RUSCONI S, LA SETA CATAMANCIO S, CITTERIO P et al.: Susceptibility to PNU-140690 (tipranavir) of human immunodeficiency virus type 1 isolates derived from patients with multidrug resistance to other protease inhibitors. Antimicrob. Agents Chemother. (2000) 44:1328-1332.
   PubMed Web of Science ®Google Scholar
• LARDER BA, HERTOGS K, BLOOR S et al.: Tipranavir inhibits broadly protease inhibitor-resistant HIV-1 clinical samples. AIDS (2000) 14:1943-1948.
   PubMed Web of Science ®Google Scholar
• BULGHERONI E, CITTERIO P, CROCE F et al.: Analysis of protease inhibitor combinations in vitro: activity of lopinavir, amprenavir and tipranavir against HIV type 1 wild-type and drug-resistant isolates. J. Antimicrob. Chemother. (2004) 53:464-468.
   PubMed Web of Science ®Google Scholar
• GHOSH AK, SHIN D, SWANSON L et al.: Structure-based design of non-peptide HIV protease inhibitors. Farmaco (2001) 56:29-32.
   PubMedGoogle Scholar
• SURLERAUX DL, DE KOCK HA, VERSCHUEREN WG et al.: Design of HIV-1 protease inhibitors active on multidrug-resistant virus. J. Med. Chem. (2005) 48:1965-1973.
   PubMed Web of Science ®Google Scholar
• SURLERAUX DL, TAHRI A, VERSCHUEREN WG et al.: Discovery and selection of TMC-114, a next generation HIV-1 protease inhibitor J. Med. Chem. (2005) 48:1813-1822.
   Web of Science ®Google Scholar
• LO CICERO M, BULGHERONI E, ZAMPIERO A et al.: TMC114: in vitro activity against HIV-1 primary isolates with reduced susceptibility to multiple protease inhibitors. 7th International Congress on Drug Therapy in HIV Infection, Glasgow, Scotland. (2004) Abstract P315.
   Google Scholar
• ARASTEH K, CLUMECK N, POZNIAK A et al.; TMC114-C207 STUDY TEAM: TMC114/ritonavir substitution for protease inhibitor(s) in a non-suppressive antiretroviral regimen: a 14-day proof-of-principle trial. AIDS (2005) 19:943-947.
   PubMed Web of Science ®Google Scholar
• KATLAMA C, BERGER D, BELLOS N et al.: Efficacy of TMC114/r in 3-class experienced patients with limited treatment options: 24-week planned interim analysis of 2 96-week multinational dose-finding trials. Proceedings of the 12th Conference on Retroviruses and Opportunistic Infections. Boston, MA, USA, Abstract 164LB (2005).
   Google Scholar
• LEE YS, LEE YS, LEE JY, KIM SN, LEE CK, PARK H: 6-Hydroxy-1,3-dioxin- 4-ones as non-peptidic HIV protease inhibitors. Bioorg. Med. Chem. Lett (2000) 10:2625-2627.
   PubMedGoogle Scholar
• HULTEN J, BONHAM NM, NILLROTH U et al.: Cyclic HIV-1 protease inhibitors derived from mannitol: synthesis, inhibitory potencies, and computational predictions of binding affinities. J. Med. Chem. (1997) 40:885-897.
   PubMed Web of Science ®Google Scholar
• BACKBRO K, LOWGREN S, OSTERLUND K et al.: Unexpected binding mode of a cyclic sulfamide HIV-1 protease inhibitor. J. Med. Chem. (1997) 40:898-902.
   PubMed Web of Science ®Google Scholar
• HULTEN J, ANDERSSON HO, SCHAAL W et al.: Inhibitors of the C(2)-symmetric HIV-1 protease: nonsymmetric binding of a symmetric cyclic sulfamide with ketoxime groups in the P2/P2' side chains. J. Med. Chem. (1999) 42:4054-4061.
   PubMed Web of Science ®Google Scholar
• AX A, SCHAAL W, VRANG L, SAMUELSSON B, HALLBERG A, KARLEN A: Cyclic sulfamide HIV-1 protease inhibitors, with sidechains spanning from P2/P2' to P1/P1'. Bioorg. Med. Chem. (2005) 13:755-764.
   PubMed Web of Science ®Google Scholar
• ALA PJ, CHANG CH: HIV aspartate proteinase: resistance to inhibitors. In: Proteinase and Peptidase Inhibition: Recent Potential Targets for Drug Development. Smith HJ, Simons C (Eds) Taylor & Francis Publishing House, London and New York, (2002):367-382.
   Google Scholar
• CHOY N, CHOI H, JUNG WH et al.: Synthesis of irreversible HIV-1 protease inhibitors containing sulfonamide and sulfone as amide bond isosteres. Bioorg. Med. Chem. Lett. (1997) 7:2635-2638.
   Google Scholar
• LU Z, BOHN J, RANO T et al.: Orally bioavailable highly potent HIV protease inhibitors against PI-resistant virus. Bioorg. Med. Chem. Lett. (2005) 15:5311-5314.
   PubMed Web of Science ®Google Scholar
• SHERRILL RG, FURFINE ES, HAZEN RJ et al.: Synthesis and antiviral activities of novel N-alkoxy- arylsulfonamide-based HIV protease inhibitors. Bioorg. Med. Chem. Lett. (2005) 15:3560-3564.
   PubMedGoogle Scholar
• CIGLER P, KOZISEK M, REZACOVA P et al.: From nonpeptide toward noncarbon protease inhibitors: metallacarboranes as specific and potent inhibitors of HIV protease. Proc. Natl. Acad. Sci. USA (2005) 102:15394-15399.
   PubMed Web of Science ®Google Scholar
• SCHÜRMANN D, GATHE J, SANNE I, WOOD R ON BEHALF OF THE SOLO STUDY TEAM: Efficacy and safety of GW433908/ritonavir once daily in therapy-naïve subjects, 48 week results: the SOLO Study. 6th International Congress on Drug Therapy in HIV Infection, Glasgow, Scotland (2002), Abstract PL14.4.
   Google Scholar
• FORD SL, REDDY YS, ANDERSON MT et al.: Single-dose safety and pharmacokinetics of brecanavir, a novel human immunodeficiency virus protease inhibitor. Antimicrob. Agents Chemother. (2006) 50:2201-2206.
   PubMedGoogle Scholar
• CARR A: Toxicity of antiretroviral therapy and implications for drug development. Nature Rev. Drug Des. (2003) 2:624-634.
   PubMed Web of Science ®Google Scholar
• ROWE TC, WEISSIG V, LAWRENCE JW: Mitochondrial DNA metabolism targeting drugs. Advan. Drug Deliv. Rev. (2001) 49:175-187.
   PubMed Web of Science ®Google Scholar
• CARR A, SAMARAS K, THORISDOTTIR A, KAUFMANN GR, CHISHOLM DJ, COOPER DA: Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet (1999) 353:2093-2099.
   PubMed Web of Science ®Google Scholar
• JAIN RG, FURFINE ES, PEDNEAULT L, WHITE AJ, LEHNARD JM: Metabolic complications associated with antiretroviral therapy. Antivir. Res. (2001) 51:151-177.
   PubMed Web of Science ®Google Scholar
• BARBARO G: HIV infection, highly active antiretroviral therapy and the cardiovascular system. Cardiovas. Res. (2003) 60:87-95.
   PubMedGoogle Scholar
• BARBARO G, KLATT EC: Highly active antiretroviral therapy and cardiovascular complications in HIV-infected patients. Curr. Pharm. Des. (2003) 9:1475-1481.
   PubMedGoogle Scholar
• VOLBERDING PA, MURPHY RL, BARBARO G et al.: The Pavia consensus statement. AIDS (2003) 17:S170-S179.
   PubMed Web of Science ®Google Scholar
• CHAI H, YAN S, LIN P, LUMSDEN AB, YAO Q, CHEN C: Curcumin blocks HIV protease inhibitor ritonavir-induced vascular dysfunction in porcine coronary arteries. J. Am. Coll. Surg. (2005) 200:820-830.
   PubMedGoogle Scholar
• CHAI H, ZHOU W, LIN P, LUMSDEN A, YAO Q, CHEN C: Ginsenosides block HIV protease inhibitor ritonavir-induced vascular dysfunction of porcine coronary arteries. Am. J. Physiol. Heart Circ. Physiol. (2005) 288:H2965-H2971.
   Google Scholar
• BOSHOFF C, WEISS R: AIDS-related malignancies. Nature Rev. Cancer (2002) 2:373-382.
   PubMed Web of Science ®Google Scholar
• MONINI P, SGADARI C, TOSCHI E, BARILLARI G, ENSOLI B: Antitumour effects of antiretroviral therapy. Nature Rev. Cancer. (2004) 4:861-875.
   PubMed Web of Science ®Google Scholar
• CATTELAN AM, CALABRO ML, AVERSA SM et al.: Regression of AIDS-related Kaposi's sarcoma following antiretroviral therapy with protease inhibitors: biological correlates of clinical outcome. Eur. J. Cancer. (1999) 35:1809-1815.
   PubMed Web of Science ®Google Scholar
• SGADARI C, MONINI P, BARILLARI G, ENSOLI B: Use of HIV protease inhibitors to block Kaposi's sarcoma and tumour growth. Lancet Oncol. (2003) 4:537-547.
   PubMed Web of Science ®Google Scholar
• SGADARI C, BARILLARI G, TOSCHI E et al.: HIV protease inhibitors are potent anti-angiogenic molecules and promote regression of Kaposi sarcoma. Nat. Med. (2002) 8:225-232.
   PubMed Web of Science ®Google Scholar
• MONINI P, SGADARI C, BARILLARI G, ENSOLI B: HIV protease inhibitors: antiretroviral agents with anti-inflammatory, anti-angiogenic and anti-tumour activity. J. Antimicrob. Chemother. (2003) 51:207-211.
   PubMedGoogle Scholar
• MAGGIORELLA L, WEN B, FRASCOGNA V, OPOLON P, BOURHIS J, DEUTSCH E: Combined radiation sensitizing and anti-angiogenic effects of ionizing radiation and the protease inhibitor ritonavir in a head and neck carcinoma model. Anticancer Res. (2005) 25:4357-4362.
   PubMedGoogle Scholar
• GUPTA AK, CERNIGLIA GJ, MICK R, MCKENNA WG, MUSCHEL RJ: HIV protease inhibitors block Akt signaling and radiosensitize tumor cells both in vitro and in vitro. Cancer Res. (2005) 65:8256-8265.
   PubMed Web of Science ®Google Scholar
• YANG Y, IKEZOE T, TAKEUCHI T et al.: HIV-1 protease inhibitor induces growth arrest and apoptosis of human prostate cancer LNCaP cells in vitro and in vitro in conjunction with blockade of androgen receptor STAT3 and AKT signaling. Cancer Sci. (2005) 96:425-433.
   PubMedGoogle Scholar
• POZIO E, MORALES MA: The impact of HIV-protease inhibitors on opportunistic parasites. Trends Parasitol. (2005) 21:58-63.
   PubMed Web of Science ®Google Scholar
• DE BERNARDIS F, TACCONELLI E, MONDELLO F et al.: Anti-retroviral therapy with protease inhibitors decreases virulence enzyme expression in vitro by Candida albicans without selection of avirulent fungus strains or decreasing their anti-mycotic susceptibility. FEMS Immunol. Med. Microbiol. (2004) 41:27-34.
   PubMedGoogle Scholar
• MIGLIORATI CA, BIRMAN EG, CURY AE: Oropharyngeal candidiasis in HIV-infected patients under treatment with protease inhibitors. Oral. Surg. Oral. Med. Oral. Pathol. Oral. Radiol. Endod. Endod. (2004) 98:301-310.
   PubMedGoogle Scholar
• ASENCIO MA, GARDUNO E, PEREZ-GIRALDO C, BLANCO MT, HURTADO C, GOMEZ-GARCIA AC: Exposure to therapeutic concentrations of ritonavir, but not saquinavir, reduces secreted aspartyl proteinase of Candida parapsilosis. Chemotherapy (2005) 51:252-255.
   PubMedGoogle Scholar
• EQUILS O, SHAPIRO A, MADAK Z, LIU C, LU D: Human immunodeficiency virus type 1 protease inhibitors block toll-like receptor 2 (TLR2)- and TLR4-Induced NF-κB activation. Antimicrob. Agents Chemother. (2004) 48:3905-3911.
   PubMed Web of Science ®Google Scholar
• RIBERA E, AZUAJE C, LOPEZ RM et al.: Once-daily regimen of saquinavir, ritonavir, didanosine, and lamivudine in HIV-infected patients with standard tuberculosis therapy (TBQD Study). J. Acquir. Immune Defic. Syndr. (2005) 40:317-323.
   PubMed Web of Science ®Google Scholar
• KABBESH M, KOOMER A, MOLTENI A, AMAJOYI R, QUINN T, HERNDON B: The effect of treatment with a protease inhibitor on mycobacterial infection. Diagn. Microbiol. Infect. Dis. (2005) 51:251-258.
   PubMedGoogle Scholar
• SKINNER-ADAMS TS, MCCARTHY JS, GARDINER DL, HILTON PM, ANDREWS KT: Antiretrovirals as antimalarial agents. J. Infect. Dis. (2004) 190:1998-2000.
   PubMed Web of Science ®Google Scholar
• PARIKH S, GUT J, ISTVAN E, GOLDBERG DE, HAVLIR DV, ROSENTHAL PJ: Antimalarial activity of human immunodeficiency virus type 1 protease inhibitors. Antimicrob. Agents Chemother. (2005) 49:2983-2985.
   PubMed Web of Science ®Google Scholar
• SAVARINO A: Expanding the frontiers of existing antiviral drugs: possible effects of HIV-1 protease inhibitors against SARS and avian influenza. J. Clin. Virol. (2005) 34:170-178.
   PubMed Web of Science ®Google Scholar